ClinicalTrials.gg
Not yet recruitingNCT07589374RIGID-TyGUpdated May 22, 2026

Cf-PWV and TyG Index Study

An observational study in Hypertension, Insulin Resistance Syndrome and Arterial Stiffness, sponsored by Hospital de Base. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Hospital de Base · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
800
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Hypertension with a site in Brazil — 28 open to participants now, 33 under way, 6 of them phase 3. Hypertension · Brazil.

Planned enrollment
7th of 18
800 · median 127
Started
2026
with 7 others
Observational
18 of 209
6 open now
Primary completion
2027-07
later than 22 of 32 live
Registered
205th of 209
by date

Among the 209 studies in Hypertension with a site in Brazil, this one is the 7th largest by planned enrollment of the 18 observational ones that give a count, is one of 8 that started in 2026, is one of 18 observational ones, reaches primary completion later than 22 of the 32 other live ones, and was the 205th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

28 of the 209 studies in Hypertension with a site in Brazil are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Hypertension with a site in Brazil, or all of them as a file.
02

Study summary

This study aims to investigate how metabolic health is related to arterial stiffness and daily blood pressure patterns. High blood pressure is one of the leading causes of heart disease worldwide, but cardiovascular risk is not determined only by average blood pressure values. Changes in blood vessel structure and metabolic function also play an important role in the development of cardiovascular disease.

Arterial stiffness reflects how flexible or rigid the arteries are. It can be measured using carotid-femoral pulse wave velocity (cf-PWV), which is considered a reliable and widely used method to assess vascular health. Increased arterial stiffness is associated with aging and higher cardiovascular risk.

At the same time, metabolic factors such as insulin resistance and central obesity are strongly linked to vascular damage. The triglyceride-glucose (TyG) index is a simple measure derived from routine blood tests and has been shown to reflect insulin resistance. Additional derived indices that combine TyG with body measurements (such as waist circumference and body mass index) may provide an even more comprehensive evaluation of metabolic risk.

Another important aspect of cardiovascular regulation is how blood pressure changes throughout the day. Blood pressure naturally rises in the morning after waking, a phenomenon known as the morning blood pressure surge. When this increase is excessive, it has been associated with a higher risk of cardiovascular events such as stroke and heart attack.

This study will evaluate the relationship between metabolic indices, arterial stiffness, and morning blood pressure patterns in adults undergoing ambulatory blood pressure monitoring as part of routine clinical care. The study will include both previously collected data and new participants evaluated using standardized methods.

No additional interventions will be performed, and all data will be collected as part of routine clinical evaluation. The results of this study may help improve cardiovascular risk assessment by integrating simple metabolic markers with vascular measurements and daily blood pressure behavior, potentially allowing earlier identification of individuals at higher risk.

Read the detailed description

Introduction

Hypertension remains a major global health problem and a leading contributor to cardiovascular morbidity and mortality. Large epidemiological studies have demonstrated a continuous and graded relationship between blood pressure levels and cardiovascular events, including myocardial infarction, stroke, and heart failure. However, traditional office blood pressure measurements do not fully capture the complexity of cardiovascular risk.

Arterial stiffness has emerged as a key marker of vascular aging and cardiovascular risk. Carotid-femoral pulse wave velocity (cf-PWV) is considered the gold standard non-invasive method for assessing aortic stiffness. Increased cf-PWV reflects cumulative vascular damage resulting from structural and functional alterations in the arterial wall, including elastin degradation, collagen deposition, vascular calcification, and endothelial dysfunction.

Insulin resistance is a central mechanism linking metabolic disorders to vascular dysfunction. It is associated with reduced nitric oxide bioavailability, increased sympathetic activity, chronic low-grade inflammation, and vascular remodeling. The triglyceride-glucose (TyG) index has been validated as a reliable surrogate marker of insulin resistance and has shown consistent associations with cardiometabolic outcomes.

Derived indices incorporating anthropometric parameters, such as TyG-WC, TyG-BMI, and TyG-WHtR, have been proposed to better capture the interaction between metabolic dysfunction and central adiposity. In addition, composite indices such as the body roundness index (BRI), metabolic score for insulin resistance (METS-IR), and cardiometabolic index (CMI) integrate multiple physiological domains and may provide incremental value in cardiovascular risk stratification.

Circadian blood pressure variation represents another important dimension of cardiovascular physiology. Blood pressure follows a daily rhythm, with a physiological increase in the early morning associated with sympathetic activation and hormonal changes. This phenomenon, known as the morning blood pressure surge (MBPS), has been associated with increased risk of cardiovascular events when exaggerated.

Arterial stiffness may amplify this morning increase in blood pressure due to reduced arterial compliance and impaired buffering of pulsatile flow. In addition, metabolic dysfunction may alter autonomic regulation and baroreflex sensitivity, further influencing circadian blood pressure patterns.

Despite strong biological plausibility, the integrated relationship between metabolic indices, arterial stiffness, and morning blood pressure parameters remains insufficiently explored. Understanding these interactions may improve early identification of individuals at increased cardiovascular risk.

Objectives

Primary Objective

To evaluate the association between arterial stiffness, measured by carotid-femoral pulse wave velocity, and the triglyceride-glucose (TyG) index.

Secondary Objectives

To assess associations between cf-PWV and TyG-derived indices (TyG-WC, TyG-BMI, TyG-WHtR); To evaluate associations between cf-PWV and composite metabolic indices (METS-IR, CMI, BRI); To investigate relationships between metabolic indices and morning blood pressure levels; To assess associations between metabolic indices and morning blood pressure surge (MBPS); To compare the performance of different metabolic indices in identifying increased arterial stiffness and morning hemodynamic load.

Methods Study Design and Data Sources

This is an observational, cross-sectional study with a prospective component, designed to evaluate the integrated relationship between metabolic indices, arterial stiffness, and circadian blood pressure patterns. The study adopts a hybrid design, combining data from two complementary sources: (1) previously collected data from an ethically approved research protocol and (2) prospectively collected data obtained under a standardized protocol.

Previously collected data will be used as secondary data, ensuring full anonymization and confidentiality. Prospectively recruited participants will provide written informed consent prior to inclusion. To ensure comparability, identical measurement protocols and definitions will be applied across both datasets.

Study Population

The study will include adults aged 18 to 65 years referred for ambulatory blood pressure monitoring (ABPM) as part of routine clinical evaluation in a specialized cardiovascular center. Participants will be included regardless of sex.

Only individuals not receiving antihypertensive treatment at the time of evaluation will be eligible for inclusion, in order to minimize the confounding effects of pharmacological therapy on arterial stiffness, metabolic indices, and circadian blood pressure patterns.

Participants will be classified according to 24-hour ABPM results into:

Normotensive individuals Untreated hypertensive individuals (defined as 24-hour mean blood pressure ≥130/80 mmHg) Clinical and Anthropometric Assessment

Baseline clinical data will include age, sex, and relevant medical history. Anthropometric measurements will be obtained using standardized procedures:

Body weight and height will be measured with participants wearing light clothing and no shoes; Body mass index (BMI) will be calculated as weight (kg) divided by height squared (m²); Waist circumference will be measured at the midpoint between the lowest rib and the iliac crest using a flexible tape measure.

In addition, the Body Roundness Index (BRI) will be calculated using a validated geometric formula incorporating waist circumference and height, providing an estimate of body fat distribution and central adiposity.

Office Blood Pressure Measurement

Office blood pressure (OBP) will be measured using a validated automated oscillometric device under standardized conditions. Measurements will be obtained after at least 5 minutes of seated rest, with the participant in a quiet environment.

Three consecutive readings will be recorded at short intervals, and the average of these measurements will be used for analysis. Heart rate will be recorded simultaneously.

Ambulatory Blood Pressure Monitoring (ABPM)

All participants will undergo 24-hour ABPM using a validated oscillometric device, applied to the non-dominant arm with an appropriately sized cuff.

The device will be programmed to obtain measurements:

Every 20 minutes during daytime (awake period) Every 30 minutes during nighttime (sleep period)

Daytime and nighttime periods will be defined based on individual sleep diaries. Only recordings meeting established quality criteria will be considered valid.

Mean systolic and diastolic blood pressure values will be calculated for:

24-hour period Daytime period Nighttime period

Hypertension will be defined based on a 24-hour mean blood pressure ≥130/80 mmHg.

Morning Blood Pressure and Morning Surge Definitions

Morning systolic and diastolic blood pressure will be defined as the average of readings obtained during the first two hours after awakening.

Morning blood pressure surge (MBPS) will be assessed using two complementary definitions:

Sleep-through MBPS (ST-MBPS): difference between morning systolic BP and the lowest nocturnal systolic BP value (including adjacent readings); Prewaking MBPS (PW-MBPS): difference between morning systolic BP and the average systolic BP during the two hours preceding awakening.

These indices will be analyzed as continuous variables and may also be evaluated across quartiles of metabolic indices.

Arterial Stiffness Assessment

Arterial stiffness will be assessed using carotid-femoral pulse wave velocity (cf-PWV), measured with a validated device under standardized conditions.

Participants will be evaluated in the supine position after at least 10 minutes of rest. Pulse waveforms will be recorded simultaneously at carotid and femoral sites.

At least three consecutive measurements will be obtained. For analysis, the mean of the two closest values will be used, provided that the difference between them is ≤0.5 m/s, ensuring measurement reproducibility and quality control.

Laboratory Data and Metabolic Indices

Laboratory data will be obtained from routine clinical tests performed under fasting conditions (minimum 8 hours), as requested by the treating physician.

The following parameters will be collected:

Fasting glucose Triglycerides HDL cholesterol

These values will be used to calculate metabolic indices:

Primary metabolic index TyG index: Ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL) / 2] Derived indices TyG-WC = TyG × waist circumference TyG-BMI = TyG × BMI TyG-WHtR = TyG × waist-to-height ratio Composite indices METS-IR: Ln [(2 × glucose) + triglycerides] × BMI / Ln (HDL-C) CMI: (waist-to-height ratio) × (triglycerides / HDL-C) BRI: geometric index of body adiposity

All indices will be analyzed both as continuous variables and categorized into quartiles.

Study Variables Primary exposure: TyG index and derived metabolic indices Primary outcome: cf-PWV

Secondary outcomes:

Morning systolic and diastolic blood pressure ST-MBPS and PW-MBPS

Potential confounders will include:

Age Sex BMI 24-hour blood pressure Hypertension status Sample Size Considerations

The sample size was defined based on the primary association between cf-PWV and the TyG index, as well as the need to perform stratified analyses.

Given planned analyses involving quartiles of metabolic indices and stratification by hypertension status, a total sample size of approximately 800 participants was established to ensure adequate statistical power and stability of subgroup estimates.

Statistical Analysis

Continuous variables will be expressed as mean ± standard deviation or median (interquartile range), depending on distribution. Categorical variables will be presented as frequencies and percentages.

Participants will be categorized into quartiles according to metabolic indices. Comparisons across quartiles will be performed using analysis of variance (ANOVA) or appropriate non-parametric tests, with evaluation of linear trends.

Associations between metabolic indices and cf-PWV, as well as between metabolic indices and morning blood pressure parameters, will be assessed using linear regression models.

Multivariable models will be adjusted for predefined confounders based on biological plausibility. Interaction terms (e.g., metabolic indices × hypertension status) will be explored.

Additional analyses may include:

Concordance correlation coefficient (Lin's CCC) Bland-Altman analysis for bias assessment

A two-sided p-value \<0.05 will be considered statistically significant.

03

Conditions studied

  • Hypertension
  • Insulin Resistance Syndrome
  • Arterial Stiffness
  • Cardiovascular Risk
  • Blood Pressure Variability

Keywords

  • Arterial stiffness
  • Pulse wave velocity
  • Triglyceride-glucose index
  • Insulin resistance
  • Ambulatory blood pressure monitoring
  • Morning blood pressure surge
  • Blood pressure variability
  • Cardiovascular risk
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of adults aged 18 to 65 years referred for ambulatory blood pressure monitoring (ABPM) as part of routine clinical evaluation at a specialized cardiovascular center. Participants will include both normotensive individuals and untreated hypertensive individuals, classified based on 24-hour ABPM measurements. The study will include both previously collected data and prospectively recruited participants evaluated using standardized protocols.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 65 years;
  • Both sexes;
  • Referred for ambulatory blood pressure monitoring (ABPM) as part of routine clinical evaluation;
  • Not receiving antihypertensive medication at the time of assessment;
  • Availability of valid 24-hour ABPM data;
  • Availability of carotid-femoral pulse wave velocity (cf-PWV) measurement;
  • Availability of fasting laboratory data, including glucose and triglycerides, for calculation of the triglyceride-glucose (TyG) index;
  • Ability and willingness to provide written (for prospectively recruited participants).

Exclusion criteria

Exclusion Criteria:

  • Use of antihypertensive medication at the time of evaluation;
  • Cardiac arrhythmias that may interfere with accurate blood pressure or pulse wave velocity measurements;
  • Invalid or poor-quality ambulatory blood pressure monitoring (ABPM) recordings;
  • Inability to obtain reliable carotid-femoral pulse wave velocity (cf-PWV) measurements;
  • Presence of severe vascular disease or conditions affecting arterial waveform assessment;
  • Missing essential clinical, laboratory, or hemodynamic data required for the primary analysis;
  • Pregnancy;
  • Refusal or inability to provide (for prospectively recruited participants).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Normotensive participants

    Adults with normal 24-hour blood pressure based on ABPM (\< 130/80 mmHg)

  • Untreated hypertensive participants

    Adults with elevated 24-hour blood pressure (≥130/80 mmHg) not receiving antihypertensive treatment.

06

What researchers measure

Primary outcomes

  1. Carotid-femoral pulse wave velocity (cf-PWV)

    Carotid-femoral pulse wave velocity (cf-PWV) will be measured as a marker of arterial stiffness using a validated non-invasive device under standardized conditions. The association between cf-PWV and the triglyceride-glucose (TyG) index will be evaluated.

    Time frame: Baseline

Secondary outcomes

  1. Morning systolic blood pressure

    Baseline

    Time frame: Average systolic blood pressure during the first two hours after awakening, obtained from 24-hour ambulatory blood pressure monitoring (ABPM).

  2. Morning diastolic blood pressure

    Baseline

    Time frame: Average diastolic blood pressure during the first two hours after awakening, obtained from ABPM.

  3. Sleep-through morning blood pressure surge

    Baseline

    Time frame: Difference between morning systolic blood pressure and the lowest nocturnal systolic blood pressure value.

  4. Prewaking morning blood pressure surge

    Baseline

    Time frame: Difference between morning systolic blood pressure and the average systolic blood pressure during the two hours preceding awakening.

07

Study locations

1 site
  • Medicine School of São José do Rio Preto
    São José do Rio Preto, São Paulo 15090-000, Brazil
    • Jose F VILELA-MARTIN, PhD · Contactvilelamartin@uol.com.br · +55 (17) 99155-5084
    • Kleber A de Oliveira, MSc · Contactkleberapoliveira095@gmail.com · +55 (17) 99209-4646
    • Luciana N COSENSO-MARTIN, PhD · Sub investigator
    • Marco A VIEIRA-da-SILVA, MSc · Sub investigator
    • Marco A de Almeida, MD · Sub investigator
08

References and documents

Publications

  • Chirinos JA, Segers P, Hughes T, Townsend R. Large-Artery Stiffness in Health and Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Sep 3;74(9):1237-1263. doi: 10.1016/j.jacc.2019.07.012. PubMed 31466622 ↗
  • Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, Schillaci G, Segers P, Vermeersch S, Weber T; Artery Society; European Society of Hypertension Working Group on Vascular Structure and Function; European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012 Mar;30(3):445-8. doi: 10.1097/HJH.0b013e32834fa8b0. PubMed 22278144 ↗
  • Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, vanMontfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y; European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014 Jul;32(7):1359-66. doi: 10.1097/HJH.0000000000000221. PubMed 24886823 ↗
  • O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, vanMontfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013 Sep;31(9):1731-68. doi: 10.1097/HJH.0b013e328363e964. PubMed 24029863 ↗
  • Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, Myers MG, Ogedegbe G, Schwartz JE, Townsend RR, Urbina EM, Viera AJ, White WB, Wright JT Jr. Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. Hypertension. 2019 May;73(5):e35-e66. doi: 10.1161/HYP.0000000000000087. PubMed 30827125 ↗
  • Johnson AW, Hissen SL, Macefield VG, Brown R, Taylor CE. Magnitude of Morning Surge in Blood Pressure Is Associated with Sympathetic but Not Cardiac Baroreflex Sensitivity. Front Neurosci. 2016 Sep 8;10:412. doi: 10.3389/fnins.2016.00412. eCollection 2016. PubMed 27660603 ↗
  • Bilo G, Grillo A, Guida V, Parati G. Morning blood pressure surge: pathophysiology, clinical relevance and therapeutic aspects. Integr Blood Press Control. 2018 May 24;11:47-56. doi: 10.2147/IBPC.S130277. eCollection 2018. PubMed 29872338 ↗
  • Renna NF, Ramirez JM, Murua M, Bernasconi PA, Repetto JM, Verdugo RA, Farez BG, Miatello RM, Diez ER. Morning blood pressure surge as a predictor of cardiovascular events in patients with hypertension. Blood Press Monit. 2023 Jun 1;28(3):149-157. doi: 10.1097/MBP.0000000000000641. Epub 2023 Apr 13. PubMed 37058087 ↗
  • Booth JN 3rd, Jaeger BC, Huang L, Abdalla M, Sims M, Butler M, Muntner P, Shimbo D. Morning Blood Pressure Surge and Cardiovascular Disease Events and All-Cause Mortality in Blacks: The Jackson Heart Study. Hypertension. 2020 Mar;75(3):835-843. doi: 10.1161/HYPERTENSIONAHA.119.14233. Epub 2020 Feb 3. PubMed 32008430 ↗
  • Bombelli M, Fodri D, Toso E, Macchiarulo M, Cairo M, Facchetti R, Dell'Oro R, Grassi G, Mancia G. Relationship among morning blood pressure surge, 24-hour blood pressure variability, and cardiovascular outcomes in a white population. Hypertension. 2014 Nov;64(5):943-50. doi: 10.1161/HYPERTENSIONAHA.114.03675. Epub 2014 Aug 25. PubMed 25156170 ↗
  • Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension. 2010 Nov;56(5):765-73. doi: 10.1161/HYPERTENSIONAHA.110.157149. Epub 2010 Oct 11. No abstract available. PubMed 20937968 ↗
  • Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003 Mar 18;107(10):1401-6. doi: 10.1161/01.cir.0000056521.67546.aa. PubMed 12642361 ↗
  • Wakabayashi I, Daimon T. The "cardiometabolic index" as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin Chim Acta. 2015 Jan 1;438:274-8. doi: 10.1016/j.cca.2014.08.042. Epub 2014 Sep 6. PubMed 25199852 ↗
  • Liu H, Meng C, Wang Z, Liu C, Yu C, Li Z. Association of Novel Insulin Resistance Indices with Blood Pressure in New-Onset Hypertension and Elevated Blood Pressure Individuals: A Cross-Sectional Study. Diabetes Metab Syndr Obes. 2023 Dec 5;16:3953-3965. doi: 10.2147/DMSO.S432049. eCollection 2023. PubMed 38077484 ↗
  • Thomas DM, Bredlau C, Bosy-Westphal A, Mueller M, Shen W, Gallagher D, Maeda Y, McDougall A, Peterson CM, Ravussin E, Heymsfield SB. Relationships between body roundness with body fat and visceral adipose tissue emerging from a new geometrical model. Obesity (Silver Spring). 2013 Nov;21(11):2264-71. doi: 10.1002/oby.20408. Epub 2013 Jun 11. PubMed 23519954 ↗
  • Xuan W, Liu D, Zhong J, Luo H, Zhang X. Impacts of Triglyceride Glucose-Waist to Height Ratio on Diabetes Incidence: A Secondary Analysis of A Population-Based Longitudinal Data. Front Endocrinol (Lausanne). 2022 Jul 22;13:949831. doi: 10.3389/fendo.2022.949831. eCollection 2022. PubMed 35937805 ↗
  • Song K, Xu Y, Wu S, Zhang X, Wang Y, Pan S. Research status of triglyceride glucose-body mass index (TyG-BMI index). Front Cardiovasc Med. 2025 Jul 18;12:1597112. doi: 10.3389/fcvm.2025.1597112. eCollection 2025. PubMed 40756600 ↗
  • Cui H, Liu Q, Wu Y, Cao L. Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study. Cardiovasc Diabetol. 2022 Feb 10;21(1):22. doi: 10.1186/s12933-022-01456-1. PubMed 35144621 ↗
  • Avagimyan A, Pogosova N, Fogacci F, Aghajanova E, Djndoyan Z, Patoulias D, Sasso LL, Bernardi M, Faggiano A, Mohammadifard N, Neglia D, Carugo S, Cicero A, Rizzo M, Biondi-Zoccai G, De Caterina R, Sarrafzadegan N. Triglyceride-glucose index (TyG) as a novel biomarker in the era of cardiometabolic medicine. Int J Cardiol. 2025 Jan 1;418:132663. doi: 10.1016/j.ijcard.2024.132663. Epub 2024 Oct 18. PubMed 39426418 ↗
  • Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008 Dec;6(4):299-304. doi: 10.1089/met.2008.0034. PubMed 19067533 ↗
  • Schram MT, Henry RM, van Dijk RA, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Westerhof N, Stehouwer CD. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension. 2004 Feb;43(2):176-81. doi: 10.1161/01.HYP.0000111829.46090.92. Epub 2003 Dec 29. PubMed 14698999 ↗
  • Kalil GZ, Haynes WG. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens Res. 2012 Jan;35(1):4-16. doi: 10.1038/hr.2011.173. Epub 2011 Nov 3. PubMed 22048570 ↗
  • Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27. doi: 10.1016/j.jacc.2009.10.061. PubMed 20338492 ↗
  • Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, Heffernan KS, Lakatta EG, McEniery CM, Mitchell GF, Najjar SS, Nichols WW, Urbina EM, Weber T; American Heart Association Council on Hypertension. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension. 2015 Sep;66(3):698-722. doi: 10.1161/HYP.0000000000000033. Epub 2015 Jul 9. No abstract available. PubMed 26160955 ↗
  • Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997 Jul 1;96(1):308-15. doi: 10.1161/01.cir.96.1.308. PubMed 9236450 ↗
  • Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13. doi: 10.1016/s0140-6736(02)11911-8. PubMed 12493255 ↗
  • Arima H, Barzi F, Chalmers J. Mortality patterns in hypertension. J Hypertens. 2011 Dec;29 Suppl 1:S3-7. doi: 10.1097/01.hjh.0000410246.59221.b1. PubMed 22157565 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will be available upon reasonable request to the corresponding author, following publication of the study results. Data sharing will be subject to approval by the responsible ethics committee and compliance with applicable data protection regulations. De-identified data may be shared for research purposes only, under a data use agreement to ensure participant confidentiality.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2026
First posted
May 15, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07589374
Lead sponsor
Hospital de Base
Responsible party
JOSE FERNANDO VILELA-MARTIN (PhD, Hospital de Base) — Principal investigator
First posted
May 15, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
May 22, 2026

Study contacts

Marco A VIEIRA-da-SILVA, MSc
Contact
vilelamartin@uol.com.br
+55 (34) 99645-0117
Marco A de Almeida, MD
Contact
telelo60@hotmail.com
+55 (34) 99122-7594
Jose F VILELA-MARTIN, PhD
principal investigator · Medicine School of São José do Rio Preto - SP - Brazil

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion